The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...

First Focal One ® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer Center OnQ ...